Molecule Details
| InChIKey | RKAHOQATMSONTM-IBGZPJMESA-N |
|---|---|
| Compound Name | Pilavapadin |
| Canonical SMILES | CC(C)C[C@](C)(N)COc1ccc(-c2ccnc(C(F)F)c2)nc1C(F)F |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 6 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 6.76 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB21552 |
|---|---|
| Drug Name | Pilavapadin |
| CAS Number | 1815613-42-3 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Pilavapadin is a small molecule drug. Pilavapadin is under investigation in clinical trial NCT06203002 (A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)). Pilavapadin has a monoisotopic molecular weight of 385.18 Da. |
Cross-references: BindingDB: 311267 CHEMBL5089410 ZINC: ZINC000584641428
Target Activities (6)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| Q2M2I8 | AAK1 | Homo sapiens | Human | PF00069 | 8.7 | IC50 | ChEMBL;BindingDB |
| Q9BUB5 | MKNK1 | Homo sapiens | Human | PF00069 | 6.8 | IC50 | ChEMBL;BindingDB |
| P23975 | SLC6A2 | Homo sapiens | Human | PF00209 | 6.4 | IC50 | ChEMBL;BindingDB |
| O14578 | CIT | Homo sapiens | Human | PF00780 PF00169 PF00069 PF00433 | 6.4 | IC50 | ChEMBL;BindingDB |
| Q9NRM7 | LATS2 | Homo sapiens | Human | PF00069 PF00433 | 6.2 | IC50 | ChEMBL;BindingDB |
| O14976 | GAK | Homo sapiens | Human | PF00069 PF10409 | 6.1 | IC50 | ChEMBL;BindingDB |